Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg

References

• Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163–179.
   Google Scholar
• Crawford J, Becker PS, Armitage JO, et al. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(12):1520–1541.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   Google Scholar
• Weycker D, Bensink MLonshteyn A, et al. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010–2016: a longitudinal assessment. Curr Med Res Opin. 2019;35(16):1073-10801–15.
   Google Scholar
• Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013;13:386.
   Google Scholar
• Buchner A, Elsasser R, Bias P. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat. 2014;148(1):107–116.
   Google Scholar
• Buchner A, Lammerich A, Abdolzade-Bavil A, et al. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin. 2014;30(12):2523–2533.
   Google Scholar
• Volovat C, Bondarenko I, Gladkov O, et al. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Support Care Cancer. 2016;24(12):4913–4920.
   Google Scholar
• Lonquex®. Summary of Product Characteristics. London: European Medicines Agency; 2013 [cited 2019 Jan 17]. Available at https://www.ema.europa.eu/documents/product-information/lonquex-epar-product-information_en.pdf.
   Google Scholar
• Pichler P, Claes N, Mazza P, et al. Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study. Ann Oncol. 2016;27(suppl 6):1459P.
   Google Scholar
• Steger G, Pichler P, Airoldi M, et al. Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: pan-European non-interventional study. Ann Oncol. 2018;29(suppl 8):viii603-viii640. mdy300.014-mdy300.014.
   Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118.
   Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 [cited 2019 Jan 17]. Available from: https://view.officeapps.live.com/op/view.aspx?src=https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/Reverse_Mapping_CTCAE_4_to_CTCAE_3.xls
   Google Scholar
• Fietz T, Luck A, Schulz H, et al. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. Curr Med Res Opin. 2019;35(7):1127–1138.
   Google Scholar
• Gladkov OA, Buchner A, Bias P, et al. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer. 2016;24(1):395–400.
   Google Scholar
• Catala G, Mebis J, Jerusalem G, et al. Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clin Belg. 2019;1–8.
   Google Scholar